La chimiothérapie d’induction dans les cancers ORL localement avancés (références)

Mis en ligne le 01/02/2001

Auteurs :

Lire l'article complet (pdf / 23,44 Ko)
  1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49(1):8-31, 1.
  2. Black RJ, Bray F, Ferlay J, Parkin DM. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990 [see comments] [published erratum appears in Eur J Cancer 1997 Dec;33(14):2440]. Eur J Cancer 1997; 33(7):1075-1107.
  3. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer [see comments]. N Engl J Med 1993; 328(3):184-194.
  4. TNM Classification of malignant tumours. UICC International Union Against Cancer. 5 ed. New-York: Wiley-Liss, Inc, 1997.
  5. Marcial VA, Pajak TF. Radiation therapy alone or in combination with surgery in head and neck cancer. Cancer 1985; 55(9 Suppl):2259-2265.
  6. Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992; 10(8):1245-1251.
  7. Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992; 10(2):257-263.
  8. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous- cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000; 355(9208):949-955.
  9. al Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998; 16(4):1310-1317.
  10. Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer [see comments]. N Engl J Med 1998; 338(25):1798-1804.
  11. Calais G, Alfonsi M, Bardet E, Sire C, Bourgeois H, Bergerot C et al. Randomized study comparing radiation alone (RT) versus RT with concomitant chemotherapy (CT) in stages III and IV oropharynx carcinoma (ARCORO). Preliminary results of the 94.01 study from the French Group of Radiation Oncology for Head and Neck Cancer (GORTEC). Proc Am Soc Clin Oncol 17, 385a. 1998.
  12. Wendt TG, Grabenbauer GG, Rodel CM, Thiel HJ, Aydin H, Rohloff R et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998; 16(4):1318-1324.
  13. Vokes EE, Kies MS, Haraf DJ, Stenson K, List M, Humerickhouse R et al. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol 2000; 18(8):1652-1661.
  14. Kotwall C, Sako K, Razack MS, Rao U, Bakamjian V, Shedd DP. Metastatic patterns in squamous cell cancer of the head and neck. Am J Surg 1987; 154(4):439-442.
  15. Brockstein BE, Haraf DJ, Kies M, Stenson K, Mittal B, Pelzer H et al. Distant metastases after concomitant chemoradiotherapy for head and neck cancer: risk is dependent upon pretreatment lymph node stage. Proc Am Soc Clin Oncol 19, a1635. 2000.
  16. Fortin A, Albert M, Eric V, Josee A. Histologic grade as an independent predictor of distant metastases in head and neck cancers. Proc Am Soc Clin Oncol 19, a1647. 2000.
  17. Bouillet T, Moere JF, Despreaux G, Herman D, Corre A, Agranat P et al. Concurrent radiotherapy and paclitaxel twice a week as radiosensitizer in stage III-IV head and neck carcinoma. Proc Am Soc Clin Oncol 19, a1670. 2000.
  18. List M, Haraf DJ, Stracks J, Stenson K, Brockstein BE, Kies M et al. Quality of life performance in head & neck cancer: comparison between paclitaxel-based and cisplatin-based concomitant chemoradiotherapy regimens. Proc Am Soc Clin Oncol 19, a1625. 2000
  19. Horiot JC, Le Fur R, N'Guyen T, Chenal C, Schraub S, Alfonsi S et al. Hyperfractionated compared with conventional radiotherapy in oropharyngeal carcinoma: an EORTC randomized trial. Eur J Cancer 1990; 26(7):779-780.
  20. Bourhis J, Lapeyre M, Rives M, Tortochaux J, Bourdin S, Leasulnier F et al. Very accelerated radiotherapy in HNSCC: results of the GORTEC 94-02 randomized trial. Proc Am Soc Clin Oncol 19, a1627. 2000.
  21. Adelstein DJ, Adams G, Li Y, Wagner H, Kish J, Ensley J et al. A phase III comparison of standard radiation therapy (RT) versus RT plus concurrent cisplatin (DDP) versus split-course RT plus concurrent DDP and 5-fluorouracll (5FU) in patients with unresectable squamous cell head and neck cancer (SCHNC). Proc Am Soc Clin Oncol 19, a1624. 2000.
  22. Brown AW, Jr., Blom J, Butler WM, Garcia-Guerrero G, Richardson MF, Henderson RL. Combination chemotherapy with vinblastine, bleomycin, and cis- diamminedichloroplatinum (II) in squamous cell carcinoma of the head and neck. Cancer 1980; 45(11):2830-2835.
  23. Randolph VL, Vallejo A, Spiro RH, Shah J, Strong EW, Huvos AG et al. Combination therapy of advanced head and neck cancer: induction of remissions with diamminedichloroplatinum (II), bleomycin and radiation therapy. Cancer 1978; 41(2):460-467.
  24. Decker DA, Drelichman A, Jacobs J, Hoschner J, Kinzie J, Loh JJ et al. Adjuvant chemotherapy with cis-diamminodichloroplatinum II and 120-hour infusion 5-fluorouracil in Stage III and IV squamous cell carcinoma of the head and neck. Cancer 1983; 51(8):1353-1355.
  25. Rooney M, Kish J, Jacobs J, Kinzie J, Weaver A, Crissman J et al. Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer 1985; 55(5):1123-1128.
  26. Vokes EE, Schilsky RL, Weichselbaum RR, Kozloff MF, Panje WR. Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol 1990; 8(2):241-247.
  27. Clark JR, Busse PM, Norris CM, Jr., Andersen JW, Dreyfuss AI, Rossi RM et al. Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for squamous cell carcinoma of the head and neck: long-term results. J Clin Oncol 1997; 15(9):3100-3110.
  28. Richard JM, Sancho H, Lepintre Y, Rodary J, Pierquin B. Intra-arterial methotrexate chemotherapy and telecobalt therapy in cancer of the oral cavity and oropharynx. Cancer 1974; 34(3):491-496.
  29. Fazekas JT, Sommer C, Kramer S. Adjuvant intravenous methotrexate or definitive radiotherapy alone for advanced squamous cancers of the oral cavity, oropharynx, supraglottic larynx or hypopharynx. Int J Radiat Oncol Biol Phys 1980; 6(5):533-541.
  30. Richard JM, Kramar A, Molinari R, Lefebvre JL, Blanchet F, Jortay A et al. Randomised EORTC head and neck cooperative group trial of preoperative intra-arterial chemotherapy in oral cavity and oropharynx carcinoma. Eur J Cancer 1991; 27(7):821-827.
  31. Jortay A, Demard F, Dalesio O, Blanchet C, DeSaulty A, Gehanno C et al. A randomized EORTC study on the effect of preoperative polychemotherapy in pyriform sinus carcinoma treated by pharyngolaryngectomy and irradiation. Results from 5 to 10 years. Acta Chir Belg 1990; 90(3):115-122.
  32. Holoye PY, Grossman TW, Toohill RJ, Kun LE, Byhardt RW, Duncavage JA et al. Randomized study of adjuvant chemotherapy for head and neck cancer. Otolaryngol Head Neck Surg 1985; 93(6):712-717.
  33. Schuller DE, Metch B, Stein DW, Mattox D, McCracken JD. Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the Southwest Oncology Group. Laryngoscope 1988; 98(11):1205-1211.
  34. A randomized trial of combined multidrug chemotherapy and radiotherapy in advanced squamous cell carcinoma of the head and neck. An interim report from the SECOG participants. South-East Co-operative Oncology Group. Eur J Surg Oncol 1986; 12(3):289-295.
  35. Pearlman NW, Johnson FB, Braun TJ, Kennaugh RC, Spofford BF, Borlase BC et al. A prospective study of preoperative chemotherapy and split-course irradiation for locally advanced or recurrent oral/pharyngeal squamous carcinoma. Am J Clin Oncol 1985; 8(6):490-496.
  36. Mazeron JJ, Martin M, Brun B, Grimard L, Lelievre G, Vergnes L et al. Induction chemotherapy in head and neck cancer: results of a phase III trial. Head Neck 1992; 14(2):85-91.
  37. Brunin F, Rodriguez J, Jaulerry C, Jouve M, Pontvert D, Point D et al. Induction chemotherapy in advanced head and neck cancer. Preliminary results of a randomized study. Acta Oncol 1989; 28(1):61-65.
  38. Jaulerry C, Rodriguez J, Brunin F, Jouve M, Mosseri V, Point D et al. Induction chemotherapy in advanced head and neck tumors: results of two randomized trials. Int J Radiat Oncol Biol Phys 1992; 23(3):483-489.
  39. T, Maipang M, Geater A, Panjapiyakul C, Watanaarepornchai S, Punperk S. Combination chemotherapy as induction therapy for advanced resectable head and neck cancer. J Surg Oncol 1995; 59(2):80-85.
  40. Adjuvant chemotherapy for advanced head and neck squamous carcinoma. Final report of the Head and Neck Contracts Program. Cancer 1987; 60(3):301-311.
  41. Salvajoli JV, Morioka H, Trippe N, Kowalski LP. A randomized trial of neoadjuvant vs concomitant chemotherapy vs radiotherapy alone in the treatment of stage IV head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 1992; 249(4):211-215.
  42. Carugati A, Pradier R, de la Torre A. Combination chemotherapy pre-radical treatment for head and neck squamous cell carcinoma. Proceedings of the American Society of Clinical Oncology 7, 152. 2000.
  43. Szpirglas H, Nizri D, Marneur M. Neoadjuvant chemotherapy. A randomized trial before radiotherapy in oral and oropharyngeal carcinomas: end results. Proceedings of the 2nd International Head and Neck Oncology Research Conference. Amsterdam, Milano: Kugler Publications, 1988: 261-264.
  44. Lewin F, Damber L, Jonsson H, Andersson T, Berthelsen A, Biorklund A et al. Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck: a randomized phase III study. Radiother Oncol 1997; 43(1):23-28.
  45. Dalley D, Beller E, Aroney R, Dewar J, Page J, Philip R et al. The value of chemotherapy (CT) prior to definitive local therapy (DTL) in patients with locally advanced squamous cell carcinoma (SCC) of the head and neck (HN). Proc Am Soc Clin Oncol 14, 297. 1995.
  46. Paccagnella A, Orlando A, Marchiori C, Zorat PL, Cavaniglia G, Sileni VC et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo [see comments]. J Natl Cancer Inst 1994; 86(4):265-272.
  47. Domenge C, Lancar R, Coche-Dequeant B, Lusinchi A, Lefebvre JL, Marandas P et al. Induction chemotherapy before radiotherapy in oropharyngeal carcinoma. Eur.J.Cancer 31A[suppl 5], S86. 1995
  48. Toohill RJ, Anderson T, Byhardt RW, Cox JD, Duncavage JA, Grossman TW et al. Cisplatin and fluorouracil as neoadjuvant therapy in head and neck cancer. A preliminary report. Arch Otolaryngol Head Neck Surg 1987; 113(7):758-761.
  49. Gedouin D, Desprez P, Perron JJ, Fleury F, Leclech G, Miglianico L et al. [Cancers of the base of the tongue and hypopharynx: results of a multicenter randomized trial of chemotherapy prior to locoregional treatment]. Bull Cancer Radiother 1996; 83(2):104-107.
  50. Martin M, Vergnes L, Lelièvre X. A randomized study of CDDP and 5-FU as neoadjuvant chemotherapy in head and neck cancer: an interim analysis. In: Banzet P, Holland JF, Khayat D, Weil M, editors. Cancer treatment: an update. Paris: Springer Verlag, 1994: 214-218.
  51. Di Blasio B, Barbieri W, Bozzetti A, Iotti C, Di Sarra S, Cocconi G. A prospective randomized trial in resectable head and neck carcinoma: loco-regional treatment with and without neoadjuvant chemotherapy. Proceedings of the American Society of Clinical Oncology 13, 279. 1994.
  52. Depondt J, Gehanno P, Martin M, Lelievre G, Guerrier B, Peytral C et al. Neoadjuvant chemotherapy with carboplatin/5-fluorouracil in head and neck cancer. Oncology 1993; 50 Suppl 2:23-27.
  53. Volling P, Schroder M. [Preliminary results of a prospective randomized study of primary chemotherapy in carcinoma of the oral cavity and pharynx]. HNO 1995; 43(2):58-64.
  54. Tejedor M, Murias A, Soria P, Aguiar J, Salinas J, Hernandez MA et al. Induction chemotherapy with carboplatin and ftorafur in advanced head and neck cancer. A randomized study. Am J Clin Oncol 1992; 15(5):417-421.
  55. Gao X, Fisher SG, Mohideen N, Emani B. Second primary cancers in patients with laryngeal cancer: a population-based study. Proc Am Soc Clin Oncol 19, a1633. 2000.
  56. Cooper JS, Pajak TF, Rubin P, Tupchong L, Brady LW, Leibel SA et al. Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys 1989; 17(3):449-456.
  57. Kim ES, Khuri FR, Lee JJ, Winn R, Cooper J, Fu KK et al. Second primary tumor incidence related to primary index tumor and smoking status in a randomized chemoprevention study of head and neck squamous cell cancer. Proc Am Soc Clin Oncol 19, a1642. 2000.
  58. van Zandwijk N, Dalesio O, Pastorino U, De Vries N, Van Tinteren H. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups [see comments]. J Natl Cancer Inst 2000; 92(12):977-986.
  59. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy [see comments]. J Clin Oncol 1999; 17(2):460-469.
  60. Al Kourainy K, Kish J, Ensley J, Tapazoglou E, Jacobs J, Weaver A et al. Achievement of superior survival for histologically negative versus histologically positive clinically complete responders to cisplatin combination in patients with locally advanced head and neck cancer. Cancer 1987; 59(2):233-238.
  61. Cognetti F, Pinnaro P, Ruggeri EM, Carlini P, Perrino A, Impiombato FA et al. Prognostic factors for chemotherapy response and survival using combination chemotherapy as initial treatment of advanced head and neck squamous cell cancer. J Clin Oncol 1989; 7(7):829-837.
  62. Spaulding MB, Fischer SG, Wolf GT. Tumor response, toxicity, and survival after neoadjuvant organ- preserving chemotherapy for advanced laryngeal carcinoma. The Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group. J Clin Oncol 1994; 12(8):1592-1599.
  63. Panis X, Coninx P, Nguyen TD, Legros M. Relation between responses to induction chemotherapy and subsequent radiotherapy in advanced or multicentric squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 1990; 18(6):1315-1318.
  64. Grabenbauer GG, Steininger H, Meyer M, Fietkau R, Brunner T, Heinkelmann P et al. Nodal CT density and total tumor volume as prognostic factors after radiation therapy of stage III/IV head and neck cancer. Radiother Oncol 1998; 47(2):175-183.
  65. Kostakoglu L, Uysal U, Ozyar E, Hayran M, Uzal D, Demirkazik FB et al. Monitoring response to therapy with thallium-201 and technetium-99m- sestamibi SPECT in nasopharyngeal carcinoma. J Nucl Med 1997; 38(7):1009-1014.
  66. Austin JR, Wong FC, Kim EE. Positron emission tomography in the detection of residual laryngeal carcinoma. Otolaryngol Head Neck Surg 1995; 113(4):404-407.
  67. Khattab J, Urba SG. Chemotherapy in head and neck cancer. Overview of newer agents. Hematol Oncol Clin North Am 1999; 13(4):753-768.
  68. Catimel G, Verweij J, Mattijssen V, Hanauske A, Piccart M, Wanders J et al. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994; 5(6):533-537.
  69. Canfield VA, Saxman SB, Kolodziej MA, Harrison-Mann B, Loehrer PJ, Vokes EE. Phase II trial of vinorelbine in advanced or recurrent squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 16, a1382. 1997.
  70. Oliveira J, Geoffrois L, Rolland F, Degardin M, Armand JP, Boudillet J et al. Activity of navelbine on lesions within previously irradiated fields in patients with metastatic and/or local recurrent squamous cell carcinoma of the head and neck: an EORTC-ECSG study. Proc Am Soc Clin Oncol 16, a1449. 1997.
  71. Smith RE, Lew D, Rodriguez GI, Taylor SA, Schuller D, Ensley JF. Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck. A phase II Southwest Oncology Group study. Invest New Drugs 1996; 14(4):403-407.
  72. Forastiere AA. Paclitaxel (Taxol) for the treatment of head and neck cancer. Semin Oncol 1994; 21(5 Suppl 8):49-52.
  73. Smith RE, Thornton DE, Allen J. A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies. Semin Oncol 1995; 22(3 Suppl 6):41-46.
  74. Fountzilas G, Athanassiadis A, Samantas E, Skarlos D, Kalogera-Fountzila A, Nikolaou A et al. Paclitaxel and carboplatin in recurrent or metastatic head and neck cancer: a phase II study. Semin Oncol 1997; 24(1 Suppl 2):S2-S2.
  75. Hitt R, Hornedo J, Colomer R, Hidalgo M, Brandariz A, Pena M et al. Study of escalating doses of paclitaxel plus cisplatin in patients with inoperable head and neck cancer. Semin Oncol 1997; 24(1 Suppl 2):S2-S2.
  76. Chougule P, Wanebo H, Akerley W, McRae R, Nigri P, Leone L et al. Concurrent paclitaxel, carboplatin, and radiotherapy in advanced head and neck cancers: a phase II study--preliminary results. Semin Oncol 1997; 24(6 Suppl 19):S19-S19.
  77. Suntharalingam M, Haas ML, Conley BA, Egorin MJ, Levy S, Sivasailam S et al. The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 2000; 47(1):49-56.
  78. Wanebo HJ, Chougule P, Ready N, Safran H, Ackerely W, Koness RJ et al. Preoperative therapy with reduced dose paclitaxel, and carboplatin and radiation achieves a similar complete response rate to a high dose regimen, but with reduced toxicity. Proc Am Soc Clin Oncol 19, a1655. 2000.
  79. Papadimitrakopoulou VA, Glisson B, Khuri FR, Lippmann SM, Ginsberg LE, Diaz EM et al. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin in patients with locally advanced squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 19. 2000.
  80. Vokes EE, Kies SM, Rosen FR, Humerickhouse RA, Stenson K, Brockstein BE et al. Induction chemotherapy followed by concomitant chemoradiotherapy for stage IV head and neck cancer: an attempt at locoregional and systemic tumor control. Proc Am Soc Clin Oncol 19. 2000.
  81. Couteau C, Chouaki N, Leyvraz S, Oulid-Aissa D, Lebecq A, Domenge C et al. A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. Br J Cancer 1999; 81(3):457-462.
  82. Catimel G, Verweij J, Mattijssen V, Hanauske A, Piccart M, Wanders J et al. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994; 5(6):533-537.
  83. Dreyfuss AI, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 1996; 14(5):1672-1678.
  84. Schoffski P, Catimel G, Planting AS, Droz JP, Verweij J, Schrijvers D et al. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. Ann Oncol 1999; 10(1):119-122.
  85. Manzione L, Caponigro F, Massa E, De Lucia L, Biglietto M, Avallone A et al. A phase II study of docetaxel (DTX) + cisplatin (CDDP) in locally advanced and metastatic squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol 18, 401a-abstract # 1537. 1999.
  86. Mel JR, Rodriguez R, Constenla M, Davial A, Fernandez-Piera M, Gonzalez-Lama J. Phase II study of docetaxel and cisplatin as induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: preliminary results. Proc Am Soc Clin Oncol 18, 401a-abstract # 1549. 1999.
  87. Biakhov M, Shah P, Betka J, Doval D, Garin A, Kawcki A et al. A Randomized Phase II Trial of Taxotere (TXT) with Cisplatin (CDDP) or TXT with 5-Fluorouracil (5FU) in Patients (PTS) with Unresectable Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN). Proc Am Soc Clin Oncol 19, 419a-abstract # 1657. 2000.
  88. Posner MR, Glisson B, al Sarraf M, Frenette WP, McLauglin WP, Norris CM et al. A multi-center phase II study of induction chemotherapy with taxotere, cisplatinum, and 5-fluorouracil (TPF) for curative treatment of locally advanced squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol 18, 394a-abstract # 1523. 1999.
  89. Schrijvers D, Van Herpen C, Kerger J, Joosens E, Le Bouder C, Casteljins J et al. Phase I-II study with docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced inoperable squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 18, 394a. 1999.
  90. Janinis J, Panagos G, Papadakou M, Xidakis E, Boukis C, Thaoukou M et al. Sequential chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (DCF) in patients with locally advanced head and neck cancer. Proc Am Soc Clin Oncol 19. 2000.
  91. Colevas AD, Busse PM, Norris CM, Fried M, Tishler RB, Poulin M et al. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial. J Clin Oncol 1998; 16(4):1331-1339.
  92. Colevas AD, Norris CM, Tishler RB, Fried MP, Gomolin HI, Amrein P et al. Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol 1999; 17(11):3503-3511.
  93. Colevas AD, Tishler RB, Fried M, Read R, DeFusco P, Norris CM et al. A phase I/II study of outpatient docetaxel, cisplatin, 5-FU, and leucovorin (OP-TPFL) as induction chemotherapy for patients with squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 19, 420a. 2000.
  94. Temam S, Flahault A, Perie S, Monceaux G, Coulet F, Callard P et al. p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol 2000; 18(2):385-394.
  95. Rosell R, Monzo M, Felip E, Astudillo J, Sanchez JJ, Rosas I et al. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. Proc Annu Meet Am Soc Clin Oncol 18, 493a. 1999.
centre(s) d’intérêt
Oncologie générale